Daehan Pharmaceutical대한약품
023910 · KOSDAQ · ₩023910 · 대한약품
Valuation model · Discounted cash flow (DCF)
We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.
Fair value per share
₩89,401
vs the current price (₩24,900)
- Enterprise value
- ₩477B
- Equity value
- ₩536B
- WACC
- 7.4%
Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.
Why the model and the price differ
The model is 259% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:
- To match today's price of ₩24,900, the model needs an operating margin of 4.8% every year (it uses 17.0%).
- Today's P/E is 5.3× against a typical 6.2× over the last 10 years.
Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.
Bear / Base / Bull
- Bear
- ₩61,232
- +145.9%
- Base
- ₩89,401
- +259.0%
- Bull
- ₩136,020
- +446.3%
Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.
Assumptions
Sign in to change the assumptions and see the results update. Sign in
Cycle options
Margin path
Every year uses the cycle-average margin (17.0%).
Revenue growth
- 4.2%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (4.2% a year, annual reports), fading to 3% by year 5.
- 3.9%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (4.2% a year, annual reports), fading to 3% by year 5.
- 3.6%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (4.2% a year, annual reports), fading to 3% by year 5.
- 3.3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (4.2% a year, annual reports), fading to 3% by year 5.
- 3%
How much sales grow that year, compared with the year before.
Default: the last 3 years' revenue growth (4.2% a year, annual reports), fading to 3% by year 5.
Business
- 17%
Operating profit as a share of revenue.
Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.
- 27.5%
Share of operating profit paid as corporate tax.
Default: Korea's top corporate tax rate (25%) plus 10% local income tax.
- 7.9%
The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).
Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).
- 9.9%
Money spent on factories, equipment, software and other long-term assets (% of revenue).
Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).
- 17.1%
Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.
Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.
Discount rate
- 2%
How fast cash flows keep growing every year after year 5.
Default: about Korea's long-run inflation plus real growth.
- 4.11%
Yield on Korea's 10-year government bond: the return with almost no risk.
Default: Korea Treasury Bond 10-year yield on 2026-10-28.
- 0.6
How much the share moves when the market moves: 1 means just like the market.
Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0, adjusted toward 1 and kept between 0.6 and 2.0.
- 5.5%
The extra return investors want for owning shares instead of bonds.
Default: a typical premium for Korean shares.
- 5.61%
The interest rate the company would pay to borrow.
Default: the 10-year yield plus a 1.5% credit spread.
Starting point
- Revenue (TTM to H1 2026)
- ₩217B
- Net debt (borrowings and leases − cash and deposits)
- −₩60B
- Shares
- 6,000,000
- Share price
- ₩24,900
- Market cap
- ₩149B
TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.
Past years and projection
Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.
| FY2023 | FY2024 | FY2025 | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₩196B | ₩204B | ₩209B | ₩226B | ₩234B | ₩243B | ₩251B | ₩258B |
| Growth | 6.3% | 4.2% | 2.2% | 4.2% | 3.9% | 3.6% | 3.3% | 3.0% |
| EBIT | ₩36B | ₩38B | ₩31B | ₩38B | ₩40B | ₩41B | ₩43B | ₩44B |
| EBIT margin | 18.3% | 18.6% | 14.9% | 17.0% | 17.0% | 17.0% | 17.0% | 17.0% |
| After-tax EBIT | ₩26B | ₩28B | ₩23B | ₩28B | ₩29B | ₩30B | ₩31B | ₩32B |
| + Depreciation | — | — | — | ₩18B | ₩19B | ₩19B | ₩20B | ₩20B |
| − Capital spending | — | ₩16B | ₩25B | ₩22B | ₩23B | ₩24B | ₩25B | ₩26B |
| − Working capital | −₩7.7B | ₩382M | ₩54B | ₩1.6B | ₩1.5B | ₩1.4B | ₩1.4B | ₩1.3B |
| Free cash flow | — | — | — | ₩22B | ₩23B | ₩24B | ₩25B | ₩25B |
| Discount factor | — | — | — | 0.931 | 0.867 | 0.807 | 0.751 | 0.700 |
| Present value | — | — | — | ₩20B | ₩20B | ₩19B | ₩18B | ₩18B |
Terminal value ₩546B, worth ₩382B today: 80% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.
Cross-check: what the market has paid before
For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:
| Low | Typical | High | |
|---|---|---|---|
| Price / book (book value ₩51,345 a share)Now 0.48× | ₩28,1840.55× | ₩35,0210.68× | ₩42,5000.83× |
| Price / earnings (last 12 months: ₩4,699 a share)Now 5.30× | ₩24,5105.22× | ₩28,9086.15× | ₩36,1907.70× |
Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.
Sensitivity
Fair value per share as two inputs change; the middle is the current case.
| WACC ↓ · Terminal growth → | 1.0% | 1.5% | 2.0% | 2.5% | 3.0% |
|---|---|---|---|---|---|
| 6.4% | ₩93,244 | ₩99,878 | ₩108,011 | ₩118,218 | ₩131,411 |
| 6.9% | ₩85,928 | ₩91,297 | ₩97,754 | ₩105,671 | ₩115,606 |
| 7.4% | ₩79,760 | ₩84,174 | ₩89,401 | ₩95,686 | ₩103,392 |
| 7.9% | ₩74,490 | ₩78,169 | ₩82,466 | ₩87,554 | ₩93,672 |
| 8.4% | ₩69,936 | ₩73,038 | ₩76,619 | ₩80,802 | ₩85,755 |
Now (TTM)
- Market cap
- ₩149B
- Enterprise value
- ₩90B
- P/E
- 5.3×
- P/B
- 0.5×
- P/S
- 0.7×
- EV/EBITDA
- —
- Dividend yield
- 4.0%
Over time (at each year end)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Price | ₩29,250 | ₩26,200 | ₩27,750 | ₩30,600 | ₩28,700 |
| Market cap | ₩176B | ₩157B | ₩167B | ₩184B | ₩172B |
| P/E | 6.3× | 4.7× | 5.9× | 7.4× | 7.6× |
| P/B | 0.6× | 0.6× | 0.7× | 0.8× | 0.8× |
| P/S | 0.8× | 0.8× | 0.8× | 1.0× | 1.0× |
| EV/EBITDA | — | — | — | — | — |
| Dividend yield | 3.4% | 3.4% | — | — | — |
Versus similar companies
| Company | P/E | P/B | P/S | EV/EBITDA | Dividend yield |
|---|---|---|---|---|---|
| Daehan Pharmaceutical | 5.3× | 0.5× | 0.7× | — | 4.0% |
| Samsung Biologics | 32.0× | 7.6× | 14.0× | — | 0.0% |
| Celltrion | 27.9× | 2.5× | 9.0× | — | 0.0% |
| Alteogen | 80.5× | 29.0× | 61.2× | — | 0.1% |
| SK biopharmaceuticals | 14.7× | 5.8× | 6.8× | — | 0.0% |
| Yuhan | 24.0× | 2.4× | 2.5× | 31.3× | 0.8% |
| HLB | — | 15.7× | 55.6× | — | 0.0% |
| Similar companies (median) | 27.9× | 6.7× | 11.5× | 31.3× | 0.0% |
Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.
Also known as: Daehan Pharmaceutical / 대한약품 / 023910 / KRX:023910
Source: KRX statistical information